A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime

被引:0
|
作者
Sánchez-Navarro, A [1 ]
Colino, CI [1 ]
Recio, MMS [1 ]
机构
[1] Univ Salamanca, Fac Farm, Dept Farm & Tecnol Farmaceut, E-37007 Salamanca, Spain
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To analyse the relationship between a series of estimated pharmacokinetic-pharmacodynamic parameters and the reported efficacy of ceftizoxime. Design: Retrospective literature search and analysis using different correlation models. Methods: The following parameters were calculated for each group of patients included in the study from the simulated plasma concentration curves corresponding to the dosage regimen administered: (i) peak concentration at steady state divided by the minimum inhibitory concentration (Cmax (SS)/MIC); (ii) the time that the plasma drug concentration exceeded the MIC scaled to 24 hours at steady state [(t(ss))(24h) > MIC]; (iii) the total area under the concentration-time curve over 24 hours at steady state divided by the MIC [(AUC(SS))(24h)/MIC]; and (iv) the AUC at steady state for the period of time that the concentration is above the MIC over a period of 24 hours divided by the MIC [(AUIC(SS))24h] A univariate correlation analysis was performed considering efficacy [rate (%) of clinical cure or bacterial eradication] as the dependent variable and the pharmacokinetic-pharmacodynamic parameter as the independent variable, using linear and nonlinear models. Results: (tss)24h > MIC was the only parameter that was statistically correlated with efficacy, the linear model being the best choice among the 4 relationship approaches tested. A biased frequency distribution of reported efficacy data constricts the correlation analysis to a narrow range of efficacy and hinders interpretation of the results. Conclusions: The reporting of cases with low efficacy rates as well as those with high efficacy rates, including information on patient idiosyncrasies and the infecting organisms, would be of great help in performing retrospective analyses of the use of antimicrobial agents, leading to the optimisation of therapy with this type of drug in clinical practice.
引用
收藏
页码:125 / 134
页数:10
相关论文
共 50 条
  • [21] Current Clinical Use of Reteplase for ThrombolysisA Pharmacokinetic-Pharmacodynamic Perspective
    Ulrich Martin
    Burchard Kaufmann
    Günter Neugebauer
    Clinical Pharmacokinetics, 1999, 36 : 265 - 276
  • [22] GENESIS OF CLINICAL PHARMACOKINETIC-PHARMACODYNAMIC CONCEPTS - MARSHALL,EK ROLE
    LEVY, G
    ANNALS OF PHARMACOTHERAPY, 1994, 28 (11) : 1300 - 1302
  • [23] Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development
    Dingemanse, Jasper
    Krause, Andreas
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 109 : S53 - S58
  • [24] Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients
    Ikawa, Kazuro
    Morikawa, Norifumi
    Uehara, Shinya
    Monden, Koichi
    Yamada, Yoshiaki
    Honda, Nobuaki
    Kumon, Hiromi
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (03) : 276 - 279
  • [25] Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity
    van Hasselt, J. G. C.
    Boekhout, A. H.
    Beijnen, J. H.
    Schellens, J. H. M.
    Huitema, A. D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (01) : 126 - 132
  • [26] Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers
    Blin, O
    Jacquet, A
    Callamand, S
    Jouve, E
    Habib, M
    Gayraud, D
    Durand, A
    Bruguerolle, B
    Pisano, P
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (04) : 510 - 512
  • [27] Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies
    Nomura, K.
    Fujimoto, Y.
    Kanbayashi, Y.
    Ikawa, K.
    Taniwaki, M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (11) : 1141 - 1143
  • [28] A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients
    Mould, D
    Chapelsky, M
    Aluri, J
    Swagzdis, A
    Samuels, R
    Granett, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (04) : 210 - 222
  • [29] Population Pharmacokinetic-Pharmacodynamic Analysis of Istradefylline in Patients With Parkinson Disease
    Knebel, William
    Rao, Niranjan
    Uchimura, T.
    Mori, Akihisa
    Fisher, Jeannine
    Gastonguay, Marc R.
    Chaikin, Philip
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (10): : 1468 - 1481
  • [30] Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats
    Ohtani, H
    Hanada, E
    Yamamoto, K
    Sawada, Y
    Iga, T
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1996, 19 (09) : 1189 - 1196